Tuesday, November 7, 2017
- 9:00AM-11:00AM
-
Abstract Number: 2603
Induction of Lupus Nephritisin in Real Situation: Cyclophosphamide or Mycophenolate Mofetil?
Systemic Lupus Erythematosus – Clinical Aspects and Treatment Poster III: Therapeutics and Clinical Trial Design- 9:00AM-11:00AM
-
Abstract Number: 2140
Infections and Medications Associated with Onset of Myositis in Myovision, a National Myositis Patient Registry
Muscle Biology, Myositis and Myopathies Poster- 9:00AM-11:00AM
-
Abstract Number: 2738
Infectious Complications in Systemic Necrotizing Vasculitides: Pooled Analysis of Five Prospective, Randomized, Controlled Trials
Vasculitis Poster III: Other Vasculitis Syndromes- 9:00AM-11:00AM
-
Abstract Number: 2354
Inflammatory Markers in Relation to Risk Factors for Cardiovascular Disease in the Pre-Symptomatic Phase of Rheumatoid Arthritis
Rheumatoid Arthritis – Clinical Aspects Poster III: Comorbidities- 9:00AM-11:00AM
-
Abstract Number: 2296
Infliximab Use in JIA and Uveitis: Does Methotrexate Help or Hinder?
Pediatric Rheumatology – Clinical and Therapeutic Aspects Poster III: Juvenile Arthritis- 9:00AM-11:00AM
-
Abstract Number: 1935
Influence of Adipokines on the Differentiation of Spongiosa-Derived Mesenchymal Stromal Cells from Osteoporosis and Osteoarthritis Patients
Biology and Pathology of Bone and Joint Poster II- 9:00AM-11:00AM
-
Abstract Number: 2525
Influence of Cardiovascular Comorbidity on Achieving Therapeutic Goals: A Comparative Study between Recent-Onset Psoriatic Arthritis and Established Disease
Spondyloarthropathies and Psoriatic Arthritis – Clinical Aspects and Treatment Poster III: Outcomes, Outcome Measures, and Comorbidities- 9:00AM-11:00AM
-
Abstract Number: 2249
Influence of Large-Joint Involvement on Patient-Physician Discordance in Global Assessment of Rheumatoid Arthritis Disease Activity Analyzed By Novel Joint Index
Patient Outcomes, Preferences, and Attitudes Poster III- 9:00AM-11:00AM
-
Abstract Number: 2564
Inhibition of Neutrophil Elastase Protects Against Glomerulonephritis and Thrombosis in a Mouse Model of Lupus
Systemic Lupus Erythematosus – Animal Models Poster- 9:00AM-11:00AM
-
Abstract Number: 2562
Inhibition of Spleen Tyrosine Kinase Improves Renal Pathology and Reduces Lymphocyte Activation in the MRL/Lpr and NZB/NZW Murine Models of Systemic Lupus Erythematosus
Systemic Lupus Erythematosus – Animal Models Poster- 9:00AM-11:00AM
-
Abstract Number: 2091
Initial Phase 2 Clinical Data of SEL-212 in Symptomatic Gout Patients: Monthly Dosing of a Pegylated Uricase (Pegsiticase) with Svp-Rapamycin Enables Sustained Reduction of Serum Uric Acid Levels By Mitigating Formation of Anti-Drug Antibodies
Metabolic and Crystal Arthropathies Poster II- 9:00AM-11:00AM
-
Abstract Number: 2252
Initial Validation of Patient-Reported Outcomes Measurement Information System (PROMIS®) in Children with Juvenile Myositis
Patient Outcomes, Preferences, and Attitudes Poster III- 9:00AM-11:00AM
-
Abstract Number: 2472
Integrated Phase 3 Safety Results of Sirukumab, an Anti–IL-6 Cytokine Monoclonal Antibody, in Patients with Active Rheumatoid Arthritis
Rheumatoid Arthritis – Small Molecules, Biologics and Gene Therapy Poster III: Efficacy and Safety of Originator Biologics and Biosimilars- 9:00AM-11:00AM
-
Abstract Number: 2552
Inter-Connections between Fatigue, Pain and Patient Global Assessement in Patients with Active Spondyloarthritis Followed in the Daily Clinic